[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053459":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Research Site","RECRUITING","Beijing","China","CN",{"type":22,"coordinates":23},"Point",[24,25],116.39723,39.9075,{"lat":25,"lon":24},[28],{"name":29,"role":11,"phone":7,"phoneExt":7,"email":30},"Shugeng Gao","gaoshugeng@cicams.ac.cn",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100053459","a-multi-centre-chart-review-study-of-stage-i-iii-non-small-cell-lung-cancer-in-china-100053459",false,"NCT07316062","A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China","A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China","MAP","Inclusion Criteria:\n\n* Stage I-III at initial NSCLC diagnosis\n* Aged ≥18 years at first diagnosis of NSCLC\n* Timeframe of NSCLC diagnosis:\n\nFor DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027\n\nExclusion Criteria:\n\n* NSCLC is not the primary cancer diagnosis\n* Patients with a recent history of other tumor or concurrent other tumor\n* Patients participating in interventional clinical trials at time of initial diagnosis\n* Patients with positive pregnancy status at the time of diagnosis","ALL","18 Years",{"count":44,"type":45},3000,"ESTIMATED","OBSERVATIONAL","This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.",[49],"Non-Small-Cell Lung",[51],"NSCLC, chart review","2026-07-10",{"date":54,"type":55},"2026-07-13","ACTUAL",{"date":57,"type":55},"2026-04-29",{"date":59,"type":45},"2029-04-30",{"name":5,"class":6},1]